Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ)
CNY 16.29
(-0.12%)
CNY 16.29
(-0.12%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.35 Billion CNY | -42.76% |
| 2022 | 2.36 Billion CNY | 75.82% |
| 2021 | 1.34 Billion CNY | 10.27% |
| 2020 | 1.21 Billion CNY | 100.95% |
| 2019 | 606.5 Million CNY | 1.21% |
| 2018 | 599.22 Million CNY | 10.82% |
| 2017 | 540.7 Million CNY | -0.24% |
| 2016 | 542.02 Million CNY | 25.91% |
| 2015 | 430.49 Million CNY | 21.44% |
| 2014 | 354.49 Million CNY | 45.11% |
| 2013 | 244.29 Million CNY | 31.48% |
| 2012 | 185.8 Million CNY | -59.08% |
| 2011 | 454.07 Million CNY | 43.89% |
| 2010 | 315.55 Million CNY | 6.18% |
| 2009 | 297.18 Million CNY | 143.36% |
| 2008 | 122.11 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 24.31 Million CNY | -89.26% |
| 2024 Q1 | 303.92 Million CNY | 174.8% |
| 2024 Q2 | 226.52 Million CNY | -25.47% |
| 2023 Q3 | 152.66 Million CNY | -62.17% |
| 2023 Q4 | -406.3 Million CNY | -366.14% |
| 2023 Q1 | 1.2 Billion CNY | 26.92% |
| 2023 Q2 | 403.5 Million CNY | -66.44% |
| 2023 FY | 1.35 Billion CNY | -42.76% |
| 2022 Q3 | 365.75 Million CNY | -35.18% |
| 2022 Q2 | 564.25 Million CNY | 16.51% |
| 2022 Q1 | 484.31 Million CNY | 302.96% |
| 2022 Q4 | 947.47 Million CNY | 159.05% |
| 2022 FY | 2.36 Billion CNY | 75.82% |
| 2021 FY | 1.34 Billion CNY | 10.27% |
| 2021 Q1 | 674.68 Million CNY | 232.98% |
| 2021 Q2 | 289.42 Million CNY | -57.1% |
| 2021 Q3 | 259.54 Million CNY | -10.32% |
| 2021 Q4 | 120.18 Million CNY | -53.69% |
| 2020 Q3 | 301.88 Million CNY | 9.27% |
| 2020 Q4 | 202.61 Million CNY | -32.88% |
| 2020 FY | 1.21 Billion CNY | 100.95% |
| 2020 Q1 | 437.97 Million CNY | 1287.14% |
| 2020 Q2 | 276.26 Million CNY | -36.92% |
| 2019 Q3 | 120.15 Million CNY | -27.79% |
| 2019 Q1 | 288.36 Million CNY | 670.79% |
| 2019 Q2 | 166.4 Million CNY | -42.29% |
| 2019 Q4 | 31.57 Million CNY | -73.72% |
| 2019 FY | 606.5 Million CNY | 1.21% |
| 2018 Q3 | 113.74 Million CNY | -17.22% |
| 2018 FY | 599.22 Million CNY | 10.82% |
| 2018 Q1 | 310.66 Million CNY | 240.23% |
| 2018 Q2 | 137.4 Million CNY | -55.77% |
| 2018 Q4 | 37.41 Million CNY | -67.11% |
| 2017 Q1 | 219.48 Million CNY | 105.59% |
| 2017 Q3 | 110.11 Million CNY | -8.09% |
| 2017 FY | 540.7 Million CNY | -0.24% |
| 2017 Q4 | 91.3 Million CNY | -17.08% |
| 2017 Q2 | 119.8 Million CNY | -45.41% |
| 2016 FY | 542.02 Million CNY | 25.91% |
| 2016 Q1 | 182.49 Million CNY | 83.02% |
| 2016 Q2 | 127.41 Million CNY | -30.18% |
| 2016 Q3 | 124.46 Million CNY | -2.31% |
| 2016 Q4 | 106.75 Million CNY | -14.23% |
| 2015 Q1 | 123.59 Million CNY | 92.72% |
| 2015 Q4 | 99.71 Million CNY | -7.68% |
| 2015 Q3 | 108 Million CNY | 8.9% |
| 2015 Q2 | 99.17 Million CNY | -19.76% |
| 2015 FY | 430.49 Million CNY | 21.44% |
| 2014 Q4 | 64.13 Million CNY | -28.13% |
| 2014 FY | 354.49 Million CNY | 45.11% |
| 2014 Q2 | 100.11 Million CNY | -0.88% |
| 2014 Q1 | 101 Million CNY | 373.47% |
| 2014 Q3 | 89.23 Million CNY | -10.87% |
| 2013 Q4 | 21.33 Million CNY | -70.07% |
| 2013 FY | 244.29 Million CNY | 31.48% |
| 2013 Q1 | 69.89 Million CNY | 175.81% |
| 2013 Q2 | 81.77 Million CNY | 16.99% |
| 2013 Q3 | 71.28 Million CNY | -12.82% |
| 2012 FY | 185.8 Million CNY | -59.08% |
| 2012 Q1 | 81.6 Million CNY | -48.47% |
| 2012 Q2 | 60.18 Million CNY | -26.24% |
| 2012 Q3 | 18.67 Million CNY | -68.97% |
| 2012 Q4 | 25.34 Million CNY | 35.69% |
| 2011 Q1 | 71.15 Million CNY | -34.67% |
| 2011 Q2 | 103.82 Million CNY | 45.93% |
| 2011 Q3 | 120.72 Million CNY | 16.28% |
| 2011 Q4 | 158.36 Million CNY | 31.18% |
| 2011 FY | 454.07 Million CNY | 43.89% |
| 2010 Q3 | 100.74 Million CNY | 0.0% |
| 2010 Q4 | 108.91 Million CNY | 8.11% |
| 2010 FY | 315.55 Million CNY | 6.18% |
| 2009 FY | 297.18 Million CNY | 143.36% |
| 2008 FY | 122.11 Million CNY | 0.0% |